Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 6, 2007

4SC Receives Patent on Rheumatoid Arthritis Candidate

  • 4SC was granted a patent related to its rheumatoid arthritis drug candidate, SC12267. The patent protects the DHODH inhibitor. SC 12267 is currently in Phase IIa trials.

    In addition, the patent also covers further back-up substances related to SC12267, medical formulations, and the treatment of patients with SC12267. The patent will apply until 2020.

    This expansion on 4SC’s patent portfolio, explains Ulrich Dauer, CEO, creates “the ideal conditions for a potential licensing partnership within the scope of this project."

  • You’re all set! Thank you for subscribing to GEN Highlights.